Biology of Bladder Cancer (R01 Clinical Trial Optional) | PAR 22 218

Opportunity Information: Apply for PAR 22 218

The Biology of Bladder Cancer (R01 Clinical Trial Optional) funding opportunity (PAR-22-218) is a National Institutes of Health (NIH) discretionary grant announcement designed to support research that digs into the fundamental biology of bladder cancer and the mechanisms that drive it. The core aim is to move beyond simply cataloging mutations or describing tumor subtypes and instead generate deeper, mechanistic insight into how bladder cancers start, evolve, recur, and become aggressive. NIH is emphasizing that bladder cancer remains a major public health issue in the United States and worldwide, in part because it occurs frequently and has a strong tendency to come back after treatment, creating a disproportionate long-term medical and economic burden.

A central theme of the announcement is that, despite major advances in molecular profiling and the identification of commonly mutated genes, many of the step-by-step biological processes that connect those genomic findings to real tumor behavior are still not well understood. The FOA highlights gaps in knowledge about initiation, progression, and malignant transformation, and it also points to a broader limitation: the field still lacks a complete understanding of normal bladder biology at the molecular, cellular, tissue, and organ levels. Because cancer is often best understood as a distortion of normal developmental and tissue-maintenance programs, the opportunity explicitly encourages proposals that study normal bladder processes alongside cancer processes, with the idea that comparing the two can reveal what goes wrong and when.

The announcement encourages projects that bring together multidisciplinary teams, reflecting the complexity of bladder cancer biology and the need to integrate different perspectives and toolsets. Competitive applications are expected to use strong biological rationale and modern approaches to clarify causal mechanisms, such as how specific pathways, cell states, microenvironmental factors, or tissue-level dynamics contribute to tumor initiation, recurrence, immune interactions, invasion, and therapy resistance. The FOA also encourages the use of clinical specimens, which signals an interest in research that is grounded in human disease and capable of producing insights that are more likely to translate into improved interventions. While the mechanism is an R01, the notice specifies "Clinical Trial Optional," meaning applicants can propose studies that do or do not include a clinical trial component, depending on what best fits the scientific question.

Eligibility is broad, spanning many types of U.S. organizations and permitting participation from foreign entities as well. Eligible applicants listed include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (other than higher education institutions); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly names additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, non-U.S. (foreign) organizations, and U.S. territories or possessions. This broad eligibility reflects a goal of expanding participation and encouraging diverse institutional contributions to bladder cancer research.

From an administrative standpoint, the opportunity is categorized as a grant in the education and health activity area and is associated with CFDA numbers 93.393 and 93.396. The original closing date provided is 2025-09-07, and the record creation date is 2022-07-26. The listing does not specify an award ceiling or expected number of awards in the provided data, which often means applicants should consult the full FOA text and NIH institute guidance for budget expectations, project period norms, and any institute-specific paylines or priorities.

Overall, this FOA is geared toward strengthening the scientific foundation of bladder cancer research by supporting mechanistic, biologically driven studies that can explain why bladder cancers behave the way they do, why they recur so often, and how normal bladder biology is altered during tumor development. The long-term intent is that clearer understanding of these underlying processes will open up better strategies for prevention, diagnosis, and treatment, including more precise interventions that target the actual drivers of disease rather than just its downstream molecular signatures.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Biology of Bladder Cancer (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.396.
• This funding opportunity was created on 2022-07-26.
• Applicants must submit their applications by 2025-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 22 218

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: